Douglas W. Wilmore
No más puestos en curso
Perfil
Douglas W.
Wilmore served as a Director at Emmaus Medical, Inc. and as an Independent Director at EMI Holding, Inc. He received his undergraduate degrees from Washburn University in 1960 and the University of Kansas in 1964.
Antiguos cargos conocidos de Douglas W. Wilmore.
| Empresas | Cargo | Fin |
|---|---|---|
EMI Holding, Inc.
 EMI Holding, Inc. Pharmaceuticals: MajorHealth Technology EMI Holding, Inc. discovers, develops, and commercializes treatments and therapies for rare diseases. The firm also engages in the marketing and sale of NutreStore L-glutamine powder for oral solution, a treatment for short bowel syndrome and the sale of L-glutamine as a nutritional supplement under the brand name AminoPure. The company was founded by Yutaka Niihara in 1987 and is headquartered in Torrance, CA. | Director/Miembro de la Junta | 01/09/2011 |
Emmaus Medical, Inc.
 Emmaus Medical, Inc. BiotechnologyHealth Technology Emmaus Medical, Inc. engages in the discovery, development and commercialization of treatments and therapies for rare diseases. Its current business is the late-stage development presently in Phase III clinical trials with the FDA of the amino acid L-glutamine as a prescription drug for the treatment of Sickle Cell Disease. The company was founded on December 20, 2000 and is headquartered in Torrance, CA. | Director/Miembro de la Junta | - |
Formación de Douglas W. Wilmore.
| University of Kansas | Undergraduate Degree |
| Washburn University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
Emmaus Medical, Inc.
Emmaus Medical, Inc. BiotechnologyHealth Technology Emmaus Medical, Inc. engages in the discovery, development and commercialization of treatments and therapies for rare diseases. Its current business is the late-stage development presently in Phase III clinical trials with the FDA of the amino acid L-glutamine as a prescription drug for the treatment of Sickle Cell Disease. The company was founded on December 20, 2000 and is headquartered in Torrance, CA. | Health Technology |
EMI Holding, Inc.
EMI Holding, Inc. Pharmaceuticals: MajorHealth Technology EMI Holding, Inc. discovers, develops, and commercializes treatments and therapies for rare diseases. The firm also engages in the marketing and sale of NutreStore L-glutamine powder for oral solution, a treatment for short bowel syndrome and the sale of L-glutamine as a nutritional supplement under the brand name AminoPure. The company was founded by Yutaka Niihara in 1987 and is headquartered in Torrance, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Douglas W. Wilmore
